ArticleJournal of inflammation research2026
A Case Report of Refractory Allergic Bronchopulmonary Aspergillosis: The Art of Selection, Discontinuation and Switching Biologics.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biologic therapies have transformed the management of allergic bronchopulmonary aspergillosis (ABPA), improving symptom control and reducing exacerbations. However, a subset of patients exhibits suboptimal or absent response to these therapies. We present a case of refractory ABPA with secondary nonresponse to omalizumab treatment, and subsequently symptom improvement after switching to mepolizumab. Case Report: A 71-year-old male patient was diagnosed with ABPA in August 2020. He was initially managed with inhaled dual therapy, itraconazole, and oral corticosteroids (OCS) for exacerbations. Since 2022, the patient has experienced recurrent acute exacerbations and disease progression, with serum total immunoglobulin E (TIgE) rising to 2150 IU/mL. Subcutaneous omalizumab 600mg every 4 weeks was initiated, which gradually reduced exacerbations and corticosteroids exposure. The biological therapy was then discontinued after 11 months treatment. In 2024, asthma symptoms were uncontrolled despite reinitiation of omalizumab therapy, with 3 exacerbations throughout the year and absolute eosinophils rose to 760 cells/μL. After full evaluation and obtaining informed consent, the patient was switched to mepolizumab in January 2025, which resulted in improved clinical and radiological outcomes. Within 6 months of combination therapy, absolute eosinophils dropped to 30 cells/μL, FEV Conclusion: Mepolizumab was effective in our patient with persistent eosinophilia and secondary nonresponse to omalizumab. Although its long-term efficacy and adverse effects require further follow-up and monitoring, our case adds clinically meaningful evidence and offers valuable insights into personalized biologic decision-making for patients with refractory ABPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.